Last reviewed · How we verify
NCT05973903
Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
Phase 1, PHASE2 trial testing Lenvatinib in GBM. Withdrawn.
1 October 2026
Quick facts
| Lead sponsor | Tel Aviv Medical Center |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 June 2024 |
| Primary completion | 1 October 2026 |
| Estimated completion | 1 October 2027 |
Drugs / interventions tested
- Lenvatinib (LENVATINIB) — full drug profile →
- Pembrolizumab (pembrolizumab) — full drug profile →
- Tumor Treating Fields (TTFields)
Conditions studied
- GBM — all drugs for GBM →
Sponsor
Tel Aviv Medical Center
Who can join
18 and older, any sex, with GBM. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This will be a prospective, open label, single center, phase I lead-in study of 10 patients to a single arm phase-II study of 37 additional patients to assess the effectiveness of pembrolizumab and lenvatinib combination therapy for recurrent glioblastoma (rGBM) patients wearing TTFields electrodes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05973903
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lenvatinib
Trials testing the same drug.
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
- NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting
- NCT07493668 — Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy · Phase 2 · not yet recruiting
Other recruiting trials for GBM
Currently open trials in the same condition.
- NCT05902169 — Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM · Phase 3 · active not recruiting
- NCT05879367 — Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma · Phase 1 · recruiting
- NCT05954858 — Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma · NA · recruiting
- NCT05933265 — Study of LP-184 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT06018363 — Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection · Phase 1, PHASE2 · recruiting
Other Tel Aviv Medical Center trials
Trials by the same sponsor.
- NCT06407310 — Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer · Phase 2 · not yet recruiting
- NCT04087616 — Internet-based CBIT for Children With Chronic Tics · NA · unknown
- NCT03222362 — Pars Plana Vitrecromy in Patients Aged 85 Years and Above · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05973903 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tel Aviv Medical Center
- Last refreshed: 4 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05973903.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing